News and Presentations

Vaxxilon awarded CARB-X grant to advance novel prophylactic vaccine to prevent Klebsiella Pneumonia infections
August 20, 2019

Vaxxilon, a privately held company working on synthetic vaccines, has been awarded a grant of up to $1.4 million from CARB-X, with the possibility of $3.1 million more based on the achievement of milestones, to develop the first prophylactic vaccine for the prevention of carbapenem resistant Klebsiella pneumoniae (crKP).

See the Vaxxilon press release (English)

siehe Pressemitteilung (Deutsche)

See the CARB-X press release

Vaxxilon Shares Transferred to Idorsia as part of the J&J Actelion Acquisition
June 16, 2017

Actelion Ltd was the principal investor and majority shareholder of Vaxxilon AG since its inception in June 2015. In association with the Actelion acquisition by Janssen Holding GmbH, an indirect subsidiary of Johnson & Johnson, Actelion carried out a demerger of Actelion’s drug discovery and early clinical pipeline assets into Idorsia, a newly formed company, headquartered in Allschwil, Switzerland. The Vaxxilon shareholding was among these assets.

Peter Seeberger Presents at the Perlen der Forschung für die Anwendung
January 13, 2017

Peter Seeberger had the opportunity to present the science, technology, and global health implications of synthetic carbohydrate vaccines at the scientific forum “Pearls of Research and Their Applications” hosted by Chancellor Angela Merkel.

The Royal Society of Chemistry
January 11, 2017

Vaxxilon aims to simplify vaccine development by replacing biological components with well-defined synthetic molecules.

Vaxxilon – Falling Walls Science Start-up of the Year 2016
November 8, 2016